🇺🇸 FDA
Pipeline program

Matching placebo tablets without active substance, BI 706321, BI 706321, BI 706321, STELARA 130 mg concentrate for solution for infusion, STELARA 90 mg solution for injection in pre-filled pen

1425-0003

Phase 2 small_molecule active

Quick answer

Matching placebo tablets without active substance, BI 706321, BI 706321, BI 706321, STELARA 130 mg concentrate for solution for infusion, STELARA 90 mg solution for injection in pre-filled pen for Crohn`s Disease (CD) is a Phase 2 program (small_molecule) at Boehringer Ingelheim International GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
Boehringer Ingelheim International GmbH
Indication
Crohn`s Disease (CD)
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials